Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.70% Shs Outstand40.37M Perf Week27.10%
Market Cap238.60M Forward P/E- EPS next Y-1.04 Insider Trans-81.97% Shs Float40.06M Perf Month30.46%
Income-19.50M PEG- EPS next Q-0.16 Inst Own65.00% Short Float5.84% Perf Quarter4.60%
Sales- P/S- EPS this Y45.40% Inst Trans-10.07% Short Ratio2.48 Perf Half Y-8.51%
Book/sh1.32 P/B4.48 EPS next Y-94.90% ROA-38.40% Target Price17.00 Perf Year405.13%
Cash/sh1.29 P/C4.59 EPS next 5Y- ROE-41.10% 52W Range1.13 - 9.87 Perf YTD-27.57%
Dividend- P/FCF- EPS past 5Y-22.30% ROI- 52W High-40.12% Beta2.60
Dividend %- Quick Ratio29.90 Sales past 5Y- Gross Margin- 52W Low423.01% ATR0.30
Employees18 Current Ratio29.90 Sales Q/Q- Oper. Margin- RSI (14)78.32 Volatility7.39% 5.77%
OptionableYes Debt/Eq0.00 EPS Q/Q43.80% Profit Margin- Rel Volume1.17 Prev Close6.02
ShortableYes LT Debt/Eq0.00 EarningsJun 05 AMC Payout- Avg Volume945.74K Price5.91
Recom2.00 SMA2022.39% SMA5030.74% SMA2007.24% Volume1,107,572 Change-1.83%
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
May-24-18 11:34AM  Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today Motley Fool +15.11%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-14-18 07:30AM  Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference GlobeNewswire
May-11-18 08:25AM  Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
May-02-18 09:33AM  Marinus Pharmaceuticals: 1Q Earnings Snapshot Associated Press +5.33%
07:30AM  Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results GlobeNewswire
Mar-08-18 07:30AM  Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-06-18 04:14PM  Biotech Jumps After Rival Pushes Back Depression Drug Tests Investor's Business Daily -13.71%
12:58PM  Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today Motley Fool
08:01AM  Marinus Pharma shares slide 14% premarket after company posts wider-than-expected loss MarketWatch
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results GlobeNewswire
Feb-23-18 02:13PM  Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Feb-07-18 08:00AM  Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab Future Expectations, Projections Moving into 2018 GlobeNewswire +5.64%
07:30AM  Marinus Pharmaceuticals to Attend Upcoming Investor Conferences GlobeNewswire
Jan-03-18 06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
Dec-28-17 09:01AM  Key Risks Facing Marinus Pharmaceuticals in December 2017 Market Realist +8.89%
07:32AM  How Do Marinus Pharmaceuticals Financials Look? Market Realist
Dec-27-17 12:45PM  Ganaxalone Faces Stiff Competition from Other Drugs under Development Market Realist
11:15AM  Why Ganaxalone Is a Promising Drug Candidate Market Realist
09:41AM  What Analysts Recommend for Marinus Pharmaceuticals in December Market Realist
Dec-21-17 07:58AM  [$$] Bain Makes Bank in Two Rebounding Biotechs Barrons.com
Dec-18-17 04:42PM  Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today Motley Fool -9.70%
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-15-17 08:20AM  Todays Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals ACCESSWIRE -15.43%
Dec-14-17 01:07PM  Here's Why Marinus Pharmaceuticals Is Soaring Today Motley Fool +15.47%
Dec-13-17 07:30AM  Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index GlobeNewswire +9.63%
Dec-08-17 08:34AM  Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News Benzinga -9.03%
Dec-07-17 04:32PM  Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday Motley Fool +39.58%
Nov-16-17 08:10AM  Market Trends Toward New Normal in Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and Charles Schwab Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-10-17 08:10AM  Todays Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc. ACCESSWIRE
Nov-09-17 12:40PM  2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why. Motley Fool +14.14%
Oct-31-17 07:39AM  Marinus Pharmaceuticals posts 3Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-30-17 02:21PM  Are Marinus Pharmaceuticals Incs (MRNS) Interest Costs Too High? Simply Wall St. -5.34%
Sep-21-17 04:01PM  Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-19-17 04:01PM  Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriters option to purchase additional shares GlobeNewswire
Sep-15-17 07:30AM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-14-17 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks -8.19%
08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries ACCESSWIRE
Sep-11-17 10:35AM  Marinus Pharma Wins Big With Mid-Stage Epilepsy Study 24/7 Wall St. +33.01%
07:30AM  Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone GlobeNewswire
Aug-15-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation ACCESSWIRE
Aug-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics ACCESSWIRE
Aug-01-17 09:32PM  Marinus Pharmaceuticals posts 2Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-30-17 10:57AM  Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US Zacks -5.52%
08:00AM  Today's Research Reports on Stocks to Watch: Inpixon and Marinus Pharmaceuticals Accesswire
Jun-29-17 02:29PM  FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder GlobeNewswire
Jun-27-17 07:30AM  Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression GlobeNewswire
May-01-17 07:36AM  Marinus Pharmaceuticals posts 1Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-18-17 07:30AM  Marinus to present Ganaxolone DATA at American academy of neurology annual meeting GlobeNewswire
Apr-11-17 07:30AM  Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer GlobeNewswire
Apr-10-17 07:30AM  Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference GlobeNewswire
Apr-05-17 09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone Business Wire
09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Mar-23-17 08:43AM  Ultragenyxs Seizure Drug Fails Study Investopedia
08:43AM  Ultragenyxs Seizure Drug Fails Study at Investopedia
Mar-22-17 04:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +5.52%
Mar-16-17 01:04PM  MARINUS PHARMACEUTICALS INC Financials
Mar-15-17 07:30AM  Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference GlobeNewswire
Mar-13-17 07:35AM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +8.97%
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results GlobeNewswire
Feb-14-17 07:30AM  Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model GlobeNewswire
Feb-01-17 04:07PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:30AM  Marinus Appoints Michael R. Dougherty to its Board of Directors GlobeNewswire
Jan-24-17 08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study Zacks
08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study
07:20AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-23-17 03:42PM  Why This Seizure Drug Matters So Much for Marinus Pharma 24/7 Wall St. +18.10%
03:42PM  Why This Seizure Drug Matters So Much for Marinus Pharma
11:20AM  Marinus Anti-Seizure Drug Did Well in Early Trial Investopedia
11:20AM  Marinus Anti-Seizure Drug Did Well in Early Trial at Investopedia
10:57AM  Marinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug at MarketWatch
07:30AM  Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder GlobeNewswire
Jan-19-17 05:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-09-17 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +11.89%
Jan-05-17 07:30AM  Marinus Provides Business Outlook for 2017 GlobeNewswire
Jan-03-17 10:40AM  Main Line biopharm firm gets a boost from the FDA at bizjournals.com
07:30AM  Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome GlobeNewswire
Nov-21-16 04:04PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Nov-17-16 12:21PM  5 Stocks Under $10 Poised for Big Breakouts
Nov-15-16 07:30AM  Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus GlobeNewswire
Nov-08-16 04:40PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 08:02AM  Marinus Pharmaceuticals posts 3Q loss -7.08%
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-24-16 06:04AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-19-16 09:54AM  Heres Why Investors Are Watching Sangamo Biosciences, GNC Holdings, and Three Other Stocks Today at Insider Monkey +5.76%
07:30AM  Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus GlobeNewswire
Oct-11-16 11:44AM  Marinus Pharmaceuticals, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
Oct-03-16 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-29-16 09:00AM  Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy GlobeNewswire -26.74%
Sep-23-16 01:45PM  Why These 5 Stocks Are Winning Today at Insider Monkey +26.14%
Sep-07-16 04:06PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
07:30AM  Marinus Appoints Seth H.Z. Fischer to its Board of Directors GlobeNewswire
Aug-09-16 07:47PM  Marinus Pharmaceuticals posts 2Q loss
04:35PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:17PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:15PM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results GlobeNewswire
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edward FCFOJan 29Sale7.913,00023,73049,800Jan 29 08:00 PM
Cashman Christopher MichaelCEOJan 18Sale6.289,56660,074247,903Jan 22 08:41 PM
Bain Capital Life Sciences Inv10% OwnerDec 19Sale7.43150,0001,114,6703,977,453Dec 19 08:30 PM
Bain Capital Life Sciences Inv10% OwnerDec 18Sale7.50300,0002,251,4404,127,453Dec 19 08:30 PM
Bain Capital Life Sciences Inv10% OwnerDec 15Sale8.10822,5476,658,6914,427,453Dec 19 08:30 PM